Sidney Response To myquestion on Alpha Article. Must read
We are not involved.
We do not expect additional filings in the near term.
We will submit additional features for clearance when we diversify into management of other chronic diseases. The reasons why we have not address the other chronic diseases are simple:
1. Diabetes is a lot more expensive to manage than the other chronic diseases.
2. A1C is a universally recognised marker on how a diabetes patient is managed. The other chronic diseases have no such market and therefore hard to demonstrate effectiveness of the process.
3. Most diabetes patients have co-morbidities, i.e. the other chronic diseases. Properly managing diabetes is a backdoor way to manage co-morbidities. For example, if a patient has diabetes and high cholesterol, if the patient is adherent to diabetes care plan the patient will likely be adherent to cholesterol care plan as well. These are future documented studies that we will sponsor.
We have tried to think through all the issues in developing our platform. Hopefully, we will be able to share the patent pending full ALRT Diabetes Management System with the public next week. You will hopefully see what I mean. We use the KISS principle – keep it simple stupid. Anything too complicated the healthcare providers will not have the time to use it. That is the problem with blood sugar management platform which ALRT and the other 3 competitors have developed. After interviewing many doctors, I came to realise that they do not have time to analyse the data. Our solution, to process the data in an easily digestible form. That can be used by the healthcare provider to manage and treat patients and at the same time easily understood by the patients as well.
That is what we have developed and submitted patents for. We have taken blood sugar management to the next level so that healthcare providers will actually use it and patients do not have to have a doctorate degree will actually understand how they need to cooperate with the healthcare provider.
Hope the OTC traders will appreciate what we are offering. I am sure that we will have the attention of the health insurance payers and also the pharmaceutical companies because adherence to care plans means selling a lot more of the pharmaceutical products.
Best
Sidney
